Evaluation of the D3 dopamine receptor selective antagonist PG01037 on l-dopa-dependent abnormal involuntary movements in rats

Rakesh Kumar, Lindsay Riddle, Suzy A. Griffin, Peter Grundt, Amy Hauck Newman, Robert R. Luedtke

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


The D3 dopamine receptor selective antagonist PG01037 has been evaluated for the ability to attenuate l-dopa-associated abnormal involuntary movements (AIMs) in unilaterally lesioned male Sprague-Dawley rats, which is a model of l-dopa-dependent dyskinesia in patients with Parkinson's Disease. The intrinsic activity of PG01037 was determined using a) a forskolin-dependent adenylyl cyclase inhibition assay with transfected HEK 293 cells expressing either the human D2Long or D3 dopamine receptor subtype and b) an assay for agonist-associated mitogenesis. For the initial experiments, the 5-HT1A receptor selective partial agonist buspirone was used as a positive control to verify our ability to quantitate changes in total AIMs and AIMs minus locomotor scores. Subcutaneous (s.c.) administration of PG01037 was found to have minimal effect on AIMs score. However, it was observed that the in vivo efficacy of PG01037 increased when administered by intraperitoneal (i.p.) injection 15 min after l-dopa/benserazide administration, as compared to a 60 min, 30 min or 0 min pretreatment. It was also found that i.p. administration of PG01037 could inhibit involuntary movements after they had achieved maximum intensity. PG01037 was found to attenuate AIM scores in these animals in a dose dependent manner with IC50 value equal to a) 7.4 mg/kg following l-dopa/benserazide administration (8 mg/kg each, i.p.) and b) 18.4 mg/kg following the administration of apomorphine (0.05 mg/kg, s.c.). However, PG01037 did not effectively inhibit SKF 81297-dependent abnormal involuntary movements. Rotarod studies indicate that PG01037 at a dose of 10 mg/kg did not adversely affect motor coordination of the unilaterally lesioned rats. Evaluation of lesioned rats using a cylinder test behavioral paradigm indicated that PG01037 did not dramatically attenuate the beneficial effects of l-dopa. These studies suggest that D3 dopamine receptor selective antagonists are potential pharmacotherapeutic candidates for the treatment of l-dopa-associated dyskinesia in patients with Parkinson's Disease.

Original languageEnglish (US)
Pages (from-to)944-955
Number of pages12
Issue number6-7
StatePublished - May 2009
Externally publishedYes

Bibliographical note

Funding Information:
The authors would like to thank Dr. Steven Gold and Mr. Brian Potts for their insightful discussions on the AIMs scoring system. We would like to thank Dr. Eunson Jung, for her assistance with the rotarod experiments. This research was supported by a Community Fast Track 2006 Award from the Michael J. Fox Foundation for Parkinson's Research and the National Institute on Drug Abuse-Intramural Research Program.


  • D3 dopamine receptors
  • Dopamine receptors
  • Dyskinesia
  • Parkinson's Disease
  • l-dopa


Dive into the research topics of 'Evaluation of the D3 dopamine receptor selective antagonist PG01037 on l-dopa-dependent abnormal involuntary movements in rats'. Together they form a unique fingerprint.

Cite this